A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
← catalyst calendarNCT06983743 · readout in 620 d
Sponsored by Erasca, Inc. (industry) · ERAS — their whole pipeline →. With Merck Sharp & Dohme LLC.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
600estimated
Sites
8
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-05 | actual | When the study began enrolling |
| Primary completion | 2028-05-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-12-01 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metastatic Solid Tumors
Interventions
- Drug: ERAS-0015
- Drug: ERAS-0015 in combination — also filed as pembrolizumab, KEYTRUDA ®, panitumumab, Vectibix, gemcitabine, Gemzar, nab-paclitaxel, Abraxane
Primary outcomes
what the primary-completion date above is the date OFDose Limiting Toxicities (DLT)
measured Study Day 1 up to Day 21
Maximum tolerated dose (MTD)
measured Study Day 1 up to Day 21
Recommended dose for expansion (RDE)
measured Study Day 1 up to Day 21
Adverse Events
measured Study Day 1 up to Day 21
Plasma concentration (Cmax)
measured Study Day 1 up to 65
Time to achieve Cmax (Tmax)
measured Study Day 1 up to 65
Area under the curve
measured Study Day 1 up to 65
Half-life
measured Study Day 1 up to 65
Permalink · ERAS's whole pipeline · Catalyst calendar · Every registered study · What changed